Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1705-1711

  Kiuchi, Katsuji ^a,b   Matsuoka, Masato ^a,b   Wu, Jenny C ^c   Silva, Raquel Lima E ^a,b   Kengatharan, Muralitharan ^d   Verghese, Mary ^d   Ueno, Shinji ^a,b   Yokoi, Katsutoshi ^a,b   Khu, Naw Htee ^a,b   Cooke, John P ^c   Campochiaro, Peter A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pre Clinical Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; VASCULOTROPIN; ISOPROTEIN; MESSENGER RNA; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHOROID; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; METABOLISM; RETINA BLOOD VESSEL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CELLS, CULTURED; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOBLOTTING; MECAMYLAMINE; MICE; MICE, INBRED C57BL; NICOTINE; NICOTINIC ANTAGONISTS; PROTEIN ISOFORMS; RECEPTORS, NICOTINIC; RETINAL VESSELS; RNA, MESSENGER;

EID: 45549103174     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0089     Document Type: Article

References (20)

1. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
2. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
3. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419 - 421.
4. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-3236.
5. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697-704.
6. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90:75-80.
7. Pontieri FE, Tanda G, Orzi F, DiChiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382:255-257.
8. Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. J Appl Physiol. 1998;84: 2089-2098.
9. Milner P, Kirkpatrick KA, Ralevic V, Toothill V, Pearson J, Burn- stock G. Endothelial cells cultured from human umbilical vein release ATP, substance P and acetylcholine in response to increased flow. Proc Biol Sci. 1990;241:245-248.
10. Wessler I, Kirkpatrick CJ, RRacke K. The cholinergic, 'pitfall',: ace- tylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol. 1999;26:198-205.
11. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogen- esis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833-839.
12. Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, Hernandez EP, Pereira-Simon S, Cousins SW. Nicotine increases size and severity of experimental choroidal neovascularization. Invest Oph-thalmol Vis Sci. 2004;45:311-317.
13. Tobe T, Ortega S, LunaJD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
14. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol. 2001;159: 313-320.
15. Espinosa-Heidmann DG, Suner IJ, Catanuto P, Hernandez EP, Marin- Castano ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47:729-737.
16. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology. 1986;93:1169-1176.
17. Ng M, Wu J, Chang E, et al. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration- novel insights into angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:106-112.
18. Heeschen C, Weis M, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest. 2002;110:527-536.
19. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovas- cular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
20. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.